💡 Click on images to switch between original and translated versions
Scene from a conference where a standing ovation follows a presentation on a new pancreatic cancer drug (said to be a subsidiary of a Korean pharmaceutical company)
Source:
https://theqoo.net/square/4226107224
https://x.com/mikito_777/status/2061388196995617266?s=46&t=kOz2rr_4a9eucY-pfm3ruA
Translation content
https://x.com/scaltritilab/status/2061184466697986322?s=46&t=kOz2rr_4a9eucY-pfm3ruA
Translation content
https://www.e-science.co.kr/news/articleView.html?idxno=130165
'Survival for 40 Months with No Trace of Cancer'... Nesuparib Presents New Possibilities for Pancreatic Cancer Treatment - Economy Science
| Reporter Kim Yeon-ok, Economy Science | Clinical results suggesting new treatment possibilities have been revealed in the field of metastatic pancreatic cancer, where survival after diagnosis is short and treatment options are limited.
www.e-science.co.kr
'Survival for 40 Months with No Trace of Cancer'... Nesuparib Presents New Possibilities for Pancreatic Cancer Treatment
Onconic Therapeutics presents Nesuparib clinical results at ASCO 2026
Clinical results suggesting new treatment possibilities have been revealed in the field of metastatic pancreatic cancer, where survival after diagnosis is short and treatment options are limited. In particular, interest in next-generation targeted anticancer drugs is rising as a case was reported where a Complete Response (CR)—a state where cancer cells disappear radiologically—was maintained for over 40 months.
(Omitted)
Researchers explained that this mechanism could potentially be expanded to various solid tumors, including ovarian, endometrial, and gastric cancers, in addition to pancreatic cancer.
(Omitted)
The article has so many technical terms that it's hard to understand T_T
Added explanations from the comments!!
Source: https://cafe.daum.net/subdued20club/ReHf/5660217